Lipum (publ), a clinical stage biopharmaceutical company developing the drug candidate SOL-116 focused on chronic inflammatory diseases, today announced its participation in the following upcoming events.

Stora Aktiedagarna | 5 March | Stockholm, Sweden

Redeye Investor Forum Online | 7 March | Digital

Biostock Health and Wealth | 11-15 March | Digital

BIO-Europe Spring | 18-20 March | Barcelona, Spain

LSX World Congress | 29-30 April | London, UK

“I am looking forward to these meetings. The first part of the clinical phase 1 study has been completed with positive results and the industry meetings provide great opportunities to present our progress. " says CEO Ola Sandborgh